Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Onconephrology
What is your approach to re-challenging patients with immune checkpoint inhibitors whom developed predominately acute tubular injury without acute interstitial nephritis?
Related Questions
Do you recommend holding ACE inhibitors, ARBs, and SGLT2 inhibitors for patients with chronic kidney disease and malignancy who are about to start high-dose intravenous methotrexate?
How would you approach management and monitoring of AL amyloidosis with isolated renal involvement?
Do you prefer monitoring creatinine over cystatin C levels in patients with lymphoma and chronic kidney disease given the potential for cystatin C levels to be increased with certain malignancies?
How long do you monitor proteinuria after starting an SGLT-2 inhibitor before considering adding another medication if proteinuria is not at goal?
What would be your approach to managing severe ANCA-associated vasculitis in a patient who is also septic from a bacterial infection?
Do you prioritize adding a GLP-1 receptor agonist over an SGLT-2 inhibitor in patients with CKD related to type 2 diabetes, uncontrolled proteinuria despite being on an ACEi, and obesity?
What are the best practices for preparing blood for transfusion in a patient with a kidney transplant to minimize complications?
Should HCQ be continued in an asymptomatic SLE patient who has received renal transplant?
Are there instances when you dose sodium zirconium cyclosilicate more than once daily for long term therapy for patients with end stage kidney disease and hyperkalemia?
Do you favor Sotagliflozin over SGLT2i alone for cardiovascular risk reduction in patients with Type 2 diabetes and chronic kidney disease?
